Journal profile · Pathology
Cytometry Part B Clinical Cytometry
ISSN 1552-4949 · eISSN 1552-4957 · Wiley-Liss Inc. · UNITED STATES · Bimonthly · Founded 2003
Cytometry Part B Clinical Cytometry: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.87; hybrid open access; APC about USD 3,800; median 125 days to acceptance (80 articles, last 24 months); community-reported acceptance: fairly easy; 66 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cytometry Part B Clinical Cytometry is published by Wiley-Liss Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Single-cell and spatial transcriptomics and Acute Myeloid Leukemia Research, together about 33.7% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Cytometry Part B: Clinical Cytometry features original research reports, in-depth reviews and special issues that directly relate to and palpably impact clinical flow, mass and image-based cytometry. These may include clinical and translational investigations important in the diagnostic, prognostic and therapeutic management of patients. Thus, we welcome research papers from various disciplines related [but not limited to] hematopathologists, hematologists, immunologists and cell biologists with clinically relevant and innovative studies investigating individual-cell analytics and/or separations. In addition to the types of papers indicated above, we also welcome Letters to the Editor, describing case reports or important medical or technical topics relevant to our readership without the length and depth of a full original report. Descriptions of these various types of submissions may be found in our ‘Instructions to Authors.’ Clinical Cytometry is the official Journal of the International Clinical Cytometry Society [ICCS] and published in affiliation with the European Society For Clinical Cell Analysis [ESCCA]. Clinical Cytometry is an official publication of the International Clinical Cytometry Society
From the journal's Aims & Scope
Research area (LetPub): Pathology
Editor-in-chief Frederic I. PrefferPublisher website
Editorial board by country: none in mainland China; most named United Kingdom 5, Italy 5, Spain 4, Canada 3, India 2 (29 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine12.3%
- Single-cell and spatial transcriptomicsBiochemistry, Genetics and Molecular Biology11.2%
- Acute Myeloid Leukemia ResearchMedicine10.2%
- Chronic Lymphocytic Leukemia ResearchMedicine8.5%
- Acute Lymphoblastic Leukemia researchMedicine6.1%
- Immune Cell Function and InteractionImmunology and Microbiology5%
- Immunodeficiency and Autoimmune DisordersImmunology and Microbiology4.3%
- Hematopoietic Stem Cell TransplantationMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medical Laboratory Technology | Zone 3 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medical Laboratory Technology | Zone 2 |
| Minor | Pathology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medical Laboratory Technology | Zone 2 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCAB AbstractsCurrent ContentsPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.87LetPub ·
- Impact factor (publisher)
- 2.9Publisher website ·
- Impact factor (publisher) 2025
- 2.9Publisher website ·
- CiteScore 2026-06
- 5.5LetPub ·
- CiteScore (publisher)
- 5.5Publisher website ·
- CiteScore (publisher) 2025
- 5.5Publisher website ·
- SJR 2026-06
- 1.03LetPub ·
- SNIP 2026-06
- 1.02LetPub ·
- h-index
- 55LetPub ·
- h-index
- 81OpenAlex ·
- i10-index
- 909OpenAlex ·
- 2-year mean citedness
- 2.15OpenAlex ·
- Self-citation rate
- 20.7%LetPub ·
- Share of gold OA articles
- 47.96%LetPub ·
Volume
- Articles per year
- 30LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 45Publisher website ·
- Downloads per year (publisher) 2025
- 467,019Publisher website ·
Articles by year OpenAlex count · 1,889 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 75 | 29 | 29 |
| 2025 | 66 | 34 | 105 |
| 2024 | 71 | 57 | 322 |
| 2023 | 51 | 44 | 286 |
| 2022 | 63 | 16 | 485 |
| 2021 | 68 | 45 | 546 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
125 daysMedian, submission to acceptance · P25–P75 71 days – 160 days
- Acceptance to online
- median 13 days (90 articles)
- Submission to online
- median 137 days
- Sample
- 80 articles with submission and acceptance dates (141 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 40%Publisher website ·
- Acceptance rate (publisher) 2025
- 40%Publisher website ·
- Submission to first decision
- 34 daysPublisher website ·
- Submission to first decision 2025
- 34 daysPublisher website ·
- Submission to acceptance 2025
- 123 daysPublisher website ·
- Acceptance to publication 2025
- 15 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,800 / EUR 3,170 / GBP 2,560 | — | — | |
| Publisher website | USD 500 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- USD 500
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Keywords
- ≤ 7
- Reference style
- Author–date
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted9
- best practiceManuscripts will appear under one of the following sections: Original Article, Review Article, Discussion Forum, Letter to the Editor, Best Practice, or Clinica…Length not stated
- clinically optimized multicolor immunofluorescence panelManuscripts will appear under one of the following sections: Original Article, Review Article, Discussion Forum, Letter to the Editor, Best Practice, or Clinica…Length not stated
- discussion forumManuscripts will appear under one of the following sections: Original Article, Review Article, Discussion Forum, Letter to the Editor, Best Practice, or Clinica…Length not stated
- letter to the editorManuscripts will appear under one of the following sections: Original Article, Review Article, Discussion Forum, Letter to the Editor, Best Practice, or Clinica…Length not stated
- opinionOriginal Articles:Manuscripts containing original work addressing the practice of clinical cytometry and the underlying methodology. Both flow or image cytometr…Length not stated
- original articleOriginal Articles:Manuscripts containing original work addressing the practice of clinical cytometry and the underlying methodology. Both flow or image cytometr…Length not stated
- reviewOriginal Articles:Manuscripts containing original work addressing the practice of clinical cytometry and the underlying methodology. Both flow or image cytometr…Length not stated
- review articleOriginal Articles:Manuscripts containing original work addressing the practice of clinical cytometry and the underlying methodology. Both flow or image cytometr…Length not stated
- viewpointOriginal Articles:Manuscripts containing original work addressing the practice of clinical cytometry and the underlying methodology. Both flow or image cytometr…Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Publication ethics, Plagiarism
- Conflicts of interest
Conflict of interest disclosure required for all authors. Model summary
Cytometry Part B: Clinical Cytometry requires that all authors disclose any potential sources of conflict of interest.
Source ↗Publisher website ·- Publication ethics
Publication ethics and COPE guidelines. Model summary
Cytometry Part B: Clinical Cytometry is committed to upholding the highest standards in research integrity and publication ethics. Wiley follows the guidelines of Committee on Publication Ethics (COPE)
Source ↗Publisher website ·- Plagiarism
Manuscripts screened for ethics issues including image screening and iThenticate. Model summary
By submitting your manuscript to the journal, your manuscript will be checked for potential ethics issues by screening images, comparing to other published works using iThenticate, as well as additional methods.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Liss Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2003
- ISSN
- 1552-4949
- Electronic ISSN
- 1552-4957
- Society / sponsor
- International Clinical Cytometry Society
- Latest issue on the website
- Volume 110, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cytometry Part B Clinical Cytometry
What CAS zone is Cytometry Part B Clinical Cytometry in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cytometry Part B Clinical Cytometry is in Zone 4 of Medicine, and in Zone 3 of the minor category Medical Laboratory Technology / Pathology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cytometry Part B Clinical Cytometry?
The latest impact factor listed by LetPub is 2.87; CiteScore 5.5, h-index 81.
How long does peer review take at Cytometry Part B Clinical Cytometry?
Based on the dates recorded on 80 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 125 days (interquartile range 71–160 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 40% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cytometry Part B Clinical Cytometry?
According to the journal's author guidelines: Keywords: ≤ 7; Reference style: Author–date; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cytometry Part B Clinical Cytometry based?
Of the 29 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (5), Italy (5) and Spain (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Cytometry Part B Clinical Cytometry?
According to LetPub and DOAJ records, Cytometry Part B Clinical Cytometry is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Cytometry Part B Clinical Cytometry open access, and what is the APC?
Cytometry Part B Clinical Cytometry is a hybrid journal. For open-access publication: APC about USD 3,800.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .